MOR103 Presentation - MorphoSys

Most Common TEAEs
Subjects with TEAEs by Preferred Term
Adverse Event
Preferred Term
Subj. with at least
one TEAE
Placebo
N=27
Total active
N=69
0.3 mg/kg
N=24
MOR 103
1.0 mg/kg
N=22
1.5 mg/kg
N=23
Placebo vs
Total Active
(Fisher‘s
Exact Test)
44.4% (n=12) 60.9% (n=42) 54.2% (n=13) 63.6% (n=14) 65.2% (n=15) 0.1733
related 25.9% (n=7) 14.5% (n=10) 12.5% (n=3) 13.6% (n=3) 17.4% (n=4) 0.2357
Nasopharyngitis 11.1% (n=3) 13.0% (n=9) 4.2% (n=1) 31.8% (n=7) 4.3% (n=1) >0.9999
Rheumatoid
Arthritis worsening
related 7.4% (n=2) 1.4% (n=1) 4.2% (n=1) 0.0% (n=0) 0.0% (n=0) 0.1900
0.0% (n=0) 13.0% (n=9) 12.5% (n=3) 18.2% (n=4) 8.7% (n=2) 0.0574
related 0.0% (n=0) 1 (1.4%) 0.0% (n=0) 4.5% (n=1) 0.0% (n=0) >0.9999
Fatigue 3.7% (n=1) 8.7% (n=6) 4.2% (n=1) 18.2% (n=4) 4.3% (n=1) 0.6690
related 0.0% (n=0) 4.3% (n=3) 4.2% (n=1) 4.5% (n=1) 4.3% (n=1) 0.5567
Hypertension 3.7% (n=1) 7.2% (n=5) 4.2% (n=1) 9.1% (n=2) 8.7% (n=2) >0.9999
related 0.0% (n=0) 1.4% (n=1) 0.0% (n=0) 4.5% (n=1) 0.0% (n=0) >0.9999
Cough 0.0% (n=0) 4.3% (n=3) 4.2% (n=1) 0.0% (n=0) 8.7% (n=2) 0.5567
related 0.0% (n=0) 0.0% (n=0) 0.0% (n=0) 0.0% (n=0) 0.0% (n=0) >0.9999
ACR/ARHP 2012 – Washington DC – November 10-14, 2012